Pressmeddelanden från Nanoform

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 02 apr 08:30

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 30 mar 20:10

Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026 19 mar 19:00

Notice to the Annual General Meeting of NANOFORM FINLAND Plc 19 mar 19:00

Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen 02 mar 15:00

Nanoform Finland Plc – Manager’s Transactions – Christian Jones 02 mar 15:00

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström 02 mar 15:00

Nanoform Finland Plc – Manager’s Transactions – David Rowe 02 mar 15:00

Nanoform Finland Plc – Manager’s Transactions – Antonio Da Silva 02 mar 15:00

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 02 mar 15:00

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 02 mar 07:10

The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees 26 feb 07:10

Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe 13 feb 10:00

Invitation to Nanoform’s Q4 and FY2025 Report Presentation 12 feb 07:00

Nanoform - Subcutaneously administered Nanotrastuzumab matches performance of Herceptin HYLECTA in minipig study 05 feb 07:05

Nanoform Finland Plc’s change negotiations have ended 29 jan 18:00

Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act 07 jan 07:05

Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 30 dec 2025 10:00

Nanoform financial calendar for 2026 16 dec 2025 06:00

Inside information: Nanoform announces new midterm business targets for 2030 13 nov 2025 07:00

Nanoform Capital Markets Day December 16th, 2025 12 nov 2025 07:10

Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set 11 nov 2025 07:00

Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License 29 okt 2025 10:00

Invitation to Nanoform’s Q3 2025 Report Presentation 27 okt 2025 08:10

Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma 21 okt 2025 08:00

Results of Nanoform Collaborative Study to be Presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) Summit 16 okt 2025 15:00

Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act 14 okt 2025 08:30

NANOFORM OUTLICENSES NANOENCORAFENIB AND SIGNS DEVELOPMENT AND COMMERCIALISATION AGREEMENT WITH A.FORALL AND IMGA 30 sep 2025 08:30

NANOFORM EXPANDS COMMERCIAL PRESENCE IN ASIA WITH A&LS PHARMA IN SOUTH KOREA 26 sep 2025 10:00

Nanoform Q3 2025 report day set for November 12th, 2025 11 sep 2025 07:10

Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit 21 aug 2025 07:10

Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results 07 aug 2025 10:00

Invitation to Nanoform’s Q2 2025 Report Presentation 19 jun 2025 08:00

NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE 17 jun 2025 19:32

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma 17 jun 2025 19:32

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 17 jun 2025 19:32

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado 17 jun 2025 19:30

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2025 on remuneration of the Board of Directors 12 jun 2025 07:10

Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide 03 jun 2025 07:10

DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN 30 maj 2025 08:45

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 30 maj 2025 08:45

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 28 maj 2025 16:00

POSITIVE NANOFORM BIOLOGICS RESPIRATORY DATA TO BE PRESENTED AT DRUG DELIVERY AND FORMULATION SUMMIT 20 maj 2025 07:10

Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS® technology 20 maj 2025 06:45

INSIDE INFORMATION MADE PUBLIC: NANOFORM PARTNERS WITH TWO SPECIALIST HEALTHCARE INVESTORS TO DEVELOP AND COMMERCIALISE NANOENCORAFENIB 06 maj 2025 10:00

Invitation to Nanoform’s Q1 2025 Report Presentation 15 apr 2025 13:10

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc 15 apr 2025 13:00

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025 17 mar 2025 16:15

Notice to the Annual General Meeting of NANOFORM FINLAND Plc 27 feb 2025 07:10

Nanoform 2024 report: Deal discussions around product kernels intensify 13 feb 2025 10:00

Invitation to Nanoform’s Q4 and FY 2024 Report Presentation 18 dec 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström 18 dec 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 18 dec 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 18 dec 2024 16:01

Nanoform Finland Plc – Managers’ transactions – Antonio Da Silva 18 dec 2024 16:00

The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees 19 nov 2024 19:45

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 19 nov 2024 19:45

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen 18 nov 2024 07:10

Nanoform Q3 2024 report: Record number of new projects signed 04 nov 2024 10:00

Invitation to Nanoform’s Q3 2024 Report Presentation 25 okt 2024 15:15

Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release 22 okt 2024 18:20

Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 05 sep 2024 07:10

Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants 29 aug 2024 07:10

Nanoform Q2 report: All business targets for 2024 on track 16 aug 2024 10:00

Invitation to Nanoform’s Q2 2024 Report Presentation 15 aug 2024 07:10

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT 14 jun 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma 14 jun 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen 14 jun 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado 14 jun 2024 16:01

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström 14 jun 2024 16:00

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2024 on remuneration of the Board of Directors 30 maj 2024 07:10

Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned 29 maj 2024 11:30

Disclosure of Major Holdings under Law 163/2024 29 maj 2024 11:30

Disclosure of Major Holdings under Law 163/2024 16 maj 2024 10:00

Invitation to Nanoform’s Q1 2024 Report Presentation 07 maj 2024 08:10

Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit 26 apr 2024 10:00

Disclosure of Major Holdings under Law 163/2024 25 apr 2024 16:00

New shares of Nanoform registered with the trade register 24 apr 2024 21:50

Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines 24 apr 2024 17:31

Nanoform announces its intention to carry out a new share issue of approximately 7 million new shares to invest in commercialization of nanoparticle enabled formulations for next generation medicines 16 apr 2024 12:50

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc 16 apr 2024 12:40

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 16, 2024 11 apr 2024 08:00

Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan 09 apr 2024 08:00

Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer 08 apr 2024 08:00

Nanoform Finland Plc: Certified Adviser change to Carnegie Investment Bank Ab 26 mar 2024 18:30

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals 12 mar 2024 17:02

Notice to the Annual General Meeting of NANOFORM FINLAND Plc 12 mar 2024 17:00

Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 and 1/2020 06 mar 2024 07:30

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström 06 mar 2024 07:30

Nanoform Finland Plc – Manager’s transactions – Mads Laustsen 06 mar 2024 07:30

Nanoform Finland Plc – Manager’s transactions – Miguel Calado 06 mar 2024 07:30

Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma 29 feb 2024 07:11

Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations 29 feb 2024 07:10

Strong momentum in Project Nanoenzalutamide 16 feb 2024 10:00

Invitation to Nanoform’s Q4 and FY 2023 Report Presentation 15 feb 2024 11:45

Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research Into Nanoparticle Enabled Formulations for Next Generation Medicines 26 jan 2024 10:20

Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide 10 jan 2024 22:01

Nanoform Finland Plc – Manager’s transactions – Antonio Da Silva 10 jan 2024 22:01

Nanoform Finland Plc – Manager’s transactions – Johanna Kause 10 jan 2024 22:01

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström